Abstract 5426
Background
The number of elderly breast cancer patients is strongly increasing due to aging. The use of a geriatric assessment in this population has been advocated in many studies and guidelines to identify high risk populations for early mortality and toxicity. Additionally, they could predict relevant outcomes such as quality of life and functional status. This systematic review summarizes all available evidence on predictive factors for disease-specific and patient-reported outcome measures in older patients with breast cancer.
Methods
We performed a systematic review of Pubmed and Embase using keywords “breast cancer”, “prediction” and “elderly” and screened all titles that were published up to June 2017 by two independent reviewers. Papers that investigated the relation between predictive markers (disease-related or patient-related) and disease-specific outcomes, toxicity or patient-reported outcomes (such as quality of life, functional status) were included.
Results
104 papers were included out of 1324 screened titles. Most studies investigated breast cancer-specific outcomes such as survival or recurrence (N = 95). The main predictors were disease-related measurements such as tumor stage or grade. However functional status, cognitive status, comorbidity and gait speed were highly predictive of overall mortality. Treatment toxicity was predicted by age, comorbidity, functional status and polypharmacy. Patient-reported outcomes such as functional status, cognitive decline and emotional functioning were studied in a minority of studies (N = 12) and were predicted by comorbidity, polypharmacy, nutritional and functional status.
Conclusions
This study shows that geriatric parameters can predict survival and patient-reported outcomes in elderly breast cancer patients. This can be used in daily clinical practice to identify patients at risk of early mortality, treatment toxicity or poor functional outcome after treatment. A minority of studies used relevant outcome measures for older patients, showing the need for studies that are tailored for the older population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1849 - Effect of thioredoxin 1 quantity detection to complement the mammography in breast cancer diagnosis
Presenter: Younju Lee
Session: Poster Display session 2
Resources:
Abstract
2221 - Identification of ultralow risk breast cancer patients (probable overdiagnosis)
Presenter: Salvador Gamez Casado
Session: Poster Display session 2
Resources:
Abstract
5291 - Prevalence of Vitamin D3 deficiency among women with early breast cancer receiving chemotherapy in an oncology dayward.
Presenter: Warner Finstad
Session: Poster Display session 2
Resources:
Abstract
4247 - Changes in ER pathway activity score during neoadjuvant letrozole to assess therapy response and predict disease free survival (DFS) in ER positive breast cancer patients
Presenter: Arran Turnbull
Session: Poster Display session 2
Resources:
Abstract
568 - Second primary malignancies in patients with breast cancer.
Presenter: Carlos Erasun Lecuona
Session: Poster Display session 2
Resources:
Abstract
1428 - Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab (TP) with either palbociclib + letrozole (Pal+L) or paclitaxel (Pac) for elderly patients with estrogen receptor & HER2 positive (ER+/HER2+) Breast Cancer (BC) (International Breast Cancer Study Group IBCSG 55-17, TOUCH)
Presenter: Laura Biganzoli
Session: Poster Display session 2
Resources:
Abstract
1479 - Neoadjuvant HER2-targeted therapy with or without immunotherapy with pembrolizumab (neoHIP): an open label randomized phase 2 trial
Presenter: Heather McArthur
Session: Poster Display session 2
Resources:
Abstract
1481 - A randomized phase 2 study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy
Presenter: Heather McArthur
Session: Poster Display session 2
Resources:
Abstract
4334 - ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in early stage triple negative breast cancer.
Presenter: Michail Ignatiadis
Session: Poster Display session 2
Resources:
Abstract
2107 - Role of Individualized Intervention(s) on Quality of Life (QOL) and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women with Early-Stage Breast Cancer (BC): MyChoice Study
Presenter: Shahid Ahmed
Session: Poster Display session 2
Resources:
Abstract